It was previously demonstrated that in ATM-deficient gastric xenografts, veliparib/irinotecan did not result in a superior tumour growth inhibition compared to veliparib alone, suggesting that the benefit could be attributed to veliparib alone and synthetic lethality [139]. This evidence concerns the gene ATM and neoplasm.